Physician

Pathology

Dr. Dipen Maru, MD

Dipen Maru is an expert in the field of Pathology. He graduated from University Hospital - University of Cincinnati College of Medicine. Dipen Maru is a published doctor as well. He has 46 publications published. The latest was: RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. He is registered with Medicare and accepts Medicare payments.

Publications

Oncologic Outcomes of Extended Robotic Resection for Rectal Cancer.
The consensus molecular subtypes of colorectal cancer.
Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection.
A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer.
Geographic Distribution of Regional Metastatic Nodes Affects the Outcome of Trimodality-Eligible Patients with Esophageal Adenocarcinoma.
Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.
Association between KRAS mutation and lung metastasis in advanced colorectal cancer.
Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer.
RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases.
Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal Cancer.
Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer.
Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation.
Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer.
Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal cancer cells.
Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer: An International Multicenter Study.
Reply to Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation...
Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial.
Locoregional Failure Rate After Preoperative Chemoradiation of Esophageal Adenocarcinoma and the Outcomes of Salvage Strategies.
RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
FXR Silencing in Human Colon Cancer by DNA methylation and KRAS Signaling.
ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after ...
The Influence of Histopathologic Tumor Viability on Long-term Survival and Recurrence Rates Following Neoadjuvant Therapy for Esophageal Adenocarcinoma.
Incidence of Brain Metastases after Trimodality Therapy in Patients with Esophageal or Gastroesophageal Cancer: Implications for Screening and Surveillance.
Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation.
Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy.
Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis ...
Predictive Biomarkers for Bevacizumab: Are We There Yet?
Loss of TGF-? Adaptor ?2SP Activates Notch Signaling and SOX9 Expression in Esophageal Adenocarcinoma.
Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1.
Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases.
Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.
Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepate...
Salvage Esophagectomy After Failed Definitive Chemoradiation for Esophageal Adenocarcinoma.
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.
MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival.
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases.
Esophageal tumor length is independently associated with long-term survival.
Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cance...
Novel endoscopic application of a new flexible-fiber CO2 laser for esophageal mucosal ablation in a porcine model.
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
High-resolution imaging in Barrett's esophagus: a novel, low-cost endoscopic microscope.
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.

Doctors Specialties

Pathology

Accepted Insurances

Education

University of Texas MD Anderson Cancer Center
University Hospital - University of Cincinnati College of Medicine
M.P. Shah Medical College

Hospital

University of Texas M.D. Anderson Cancer Center

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1679688832
Last Name Of The Provider	MARU
First Name Of The Provider	DIPEN
View All

Similar Doctors

	Dr. Mary V. Gresik, MD This Doctor is OpenDoctor Recommended.
	Dr. Mojghan Amrikachi, MD This Doctor is OpenDoctor Recommended.
	Dr. Roupen H. Dekmezian, MD This Doctor is OpenDoctor Recommended.
	Dr. Joe G. Ford, MD This Doctor is OpenDoctor Recommended.
	Dr. Nathan E. Lee, MD
	Dr. Guilin Tang, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Kristine Konopka, MD This Doctor is OpenDoctor Recommended.